"Liarozole"^^ . "Pharmacologic Substance"^^ . . "R 75251CNNCI" . "Liarozole"^^ . "LIAROZOLEPTFDAK0Q29TGV9Y" . "115575-11-6"^^ . . "LiarozolePTNCI" . . "C17H13ClN4"^^ . "LiazalBRNCI" . "K0Q29TGV9Y"^^ . "C1433"^^ . "1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-SNNCI" . "FDA"^^ . . "An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.NCI" . "C0165479"^^ . . "Organic Chemical"^^ . "An anticancer drug that promotes differentiation by increasing the levels of retinoic acid within the tumor.NCI-GLOSS" . "LiarozolePTDCP31430" . . "Liarozole"^^ . "R-61405SYNCI" . "liarozolePTNCI-GLOSSCDR0000045752" .